NZEVA Prohibited Substance Recommended Withholding Times October 2011

Total Page:16

File Type:pdf, Size:1020Kb

NZEVA Prohibited Substance Recommended Withholding Times October 2011 NZEVA Prohibited Substance Recommended Withholding Times October 2011 Name of Drug Brand Name Route Dose Recommended Withholding Times (days) Acepromazine Sedazine paste,Acezine inj etc i/m,i/v,po 30mg i/m 4d Acetylsalicylic Acid Vetalgine, Aspirin i/v,po 10gm 3d Azadirachitins ( phytosterols) insect growth inhibitors topical nil ACTH Synacthen i/v,i/m 3d Albroxol Nil Albuterol, Salbutamol Ventolin inhalation 3d Altrenogest Regumate po Nil Antiparasitics ( NOT Piperazine or Imidazothiazoles group) Nil Aminocaprioc acid Amicar 3d Amitraz Topical 2d Amiodarone Aratc,Cardinorm po,i/v 5mg/kg 19d Aminorex ( byproduct of Levamizole) Nilverm drench po i/v 4d Arnica plant extracts topical 3d Atropine i/m, i/v 3d Belladonna Dr Bells po 3d Benzocaine Aureomycin Powder Topical 4d Beclomethasone diproprionate Qvar, Beconase Hayfever aerosol 3d Betamethasone NaPO4/Betamethasone Acetate solution Celestone i/a 5.7mg 4d Betamethasone Betsolan i/m 20mg 8d Boldenone Undecylenate Boldebal-H i/m 25Omg 30d (can be variable) Bromhexine HCl Bromotrimide etc PO Nil Butanol (N-Butyl Alcohol) po 3d Butorphanol Butorphic, Dorolex i/v 100ug/kg 3d Capsican Topical 2d Caffeine Itz Majic po 11d Carprofen Rimadyl i/v 400mg 11d (15d multiples) Celecoxib po 2.5 gm 5d Chloramphenicol Chlorsig eye ointment Topical Nil Chlorpromazine Largactil po 240mg 5d Chrondroitin Sulphate Cosequin po Nil Clanobutin Bykahepar i/v 4.5gm 4d Clenbuterol HCl Ventipulmin granules po 50mg daily 5d Comfrey plant po 3d Cromgylcolate Vircom inhaler inhaler 4d NZEVA Page 1 of 5 NZEVA Prohibited Substance Recommended Withholding Times October 2011 Name of Drug Brand Name Route Dose Recommended Withholding Times (days) Copper Indomethacin Cu Algesic po 200mg (5ml) 4d Cyproheptadine Periactin po 8d Dantrolene po 1gm 4d Dembrexine Sputolysin po Nil Detomidine Dormosedan i/v 4d Dexamethasone Acetate Naquasone po 1 bolus 3d Dexamethasone Na Phosphate Dexadresson, Dexone 5 i/v, i/m 100mg 3d Dexamethasone phenylproprionate Dexafort i/m 10ml 9d Dexamethasone-21-isonicotinate Voren Depot i/m 30mg (10ml) 13d Dexamethasone Trimethylacetate Tridexine i/m 25mg (5ml) 15+days Devils Claw Various po 3d Dextromoramide Palfium po 200mg 3d Diazepam Valium, Pamlin po,i/v 16d Diclofenac Voltaren po,topical 4d Digitalis 3d Dimethylsulfoxide DMSO po,i/v 50gm 3d Diphenhydramine HCl Ranilixa po 85mg 3d Dipyrone Buscopan i/v 10gm 4d Domperidone po 500mg 5d Anti-GnRH vaccine Equity prohibited for racing/breeding Etamiphylline camsylate Delcam inj, Millophyline V inj i/v 3mg/kg Ethylestrolone Nitrotain po 3d Flumethazone Flucort i/m 2.5mg 6d Flunixin Meglumine Finadyne i/v 500mg 4d Fluphenazine Modecate i/m 65d Fluticasone Flixotide inhalation 5d Frusemide Salix i/v 1.0mg/kg 4d Gentamicin Gentocin inj i/m,i/v Nil Growth Hormone EquiGen i/m 10-20 mgm/kg 3d Glyceryl guaiacolate (Guiafenesin) Giafen i/v 4d Ginsenosides Gingseng po 3d Glucosamine Cosequin po Nil Glycopyrronium Bromide Robinul Glycosate vet i/v 2mg 3d Heparoid mucopolysaccarides Hurudoid topical 3d NZEVA Page 2 of 5 NZEVA Prohibited Substance Recommended Withholding Times October 2011 Name of Drug Brand Name Route Dose Recommended Withholding Times (days) Heptaminol Kynoselen with heptaminol i/v 20ml 4d Hydrocortisone sodium succinate Solu-Delta -Cortef (human prep) i/v 100mg 4d Hydroxy-progesterone caproate Hydroxy-P 500 i/m 500mg 15d Hydroxy-progesterone hexonate lutogeston i/m 1.25gm 15d Ipatropium bromide Atrovent inhalation 0.4-0.8ug/kg 3d Isoxuprine lactate Circulon po variable 42d+ do not use Ketamine Ketamine inj i/v 700mg 5d Ketoprofen KetofenTM 100mg/ml solution i/v 1gm 4d Lignocaine Local po,s/c 400mg 4d Lornoxicam Xefo Tabs po 1.5gm 3d Meclofenamic Acid Arquel Granules po 1gm 4d Meloxicam Metacam po,i/m 4d Menthol Breathe Easy Nil at "normal" doses Mepivacaine Mepivicaine s/c 400mg 3d Mepyramine Maleate Atimine i/m 4d Methandriol Diproprionate Orabol-H po,i/m 50d Methimazole Carbimazole po 4d Methylprednisolone Depo-Medrol i/ articular 240mg 25 d (17d on 120mg) Methyl progesterone acetate Depo Provera i/m 200+ days Methylprednisolone Depo-Medrol i/m 200mg (5ml) 46+d methylsulfonymethane MSM po 1gm 3d Metronidazole Trichozole, Flagyl po Nil Nandrolone Deconate Tribolin75 i/m 50d Nandrolone Laurate Laurobolin i/m 90d Nandrolone Phenylpropionate Nandrolin i/m 470mg 40d Natamycin Mycophyt Topical Nil N-butylscopolammonium Bromide Buscopan i/v 3d (4d for Dipyrone) Neem Oil po/ topical Nil Neomycin Nil Neostigmine Bromide 3d Nitrofurazone Nitrofurazone ointment topical nil Omeprazole Losec po Nil Paracetamol Panadol po 3d Pentosan Polysulphate Pentosan inj i/m 1500mg Nil NZEVA Page 3 of 5 NZEVA Prohibited Substance Recommended Withholding Times October 2011 Name of Drug Brand Name Route Dose Recommended Withholding Times (days) Pentofflyine Kelato Appetite po 2d Pentoxifylline Trental po 4d Pentazocaine i/v 300mg 8d Pergolide po 0.01mg/kg 9d Pethidine i/m 2.0mg/kg 4d Phenylbutazone Equipalazone, Bute i/v paste etc i/v,po 3gm 6d (11d on multiples) Phenytoin Dilantin po 7d Polysulphonated Glycosglycans Adequan i/m Nil Prednisolone Eye preps Topical 4d Prednisolone granules Preddy granules po 4d (2X on multiples) Prednisone sodium succinate Solu-Delta-Cortef (Vet) i/v,i/m 100mg 4d Prilocaine s/c 400mg 3d Procaine Penicillin Various i/m 22d (can be variable) Procaine Salt (Not in Penicillin) 4d Progesterone i/m Nil Promazine PromAce po 8d Promethazine Phenergan i/m 500mg 6d Propantheline Bromide Propan-B i/v 100mg 3d Pseudoephedrine Herbal preps po 6d Quinidine Kinidin Durules po 5gm 11d Pyrilamine Histantin i/m 8d Ranitidine HCl Zantac po 3d Reserpine Rakelin i/m 8d Rofecoxib po 250mg 5d Romifidine SedivetTM 10mg/ml solution i/v 100ug/kg 4d Sassafras Penetrene topical 2d Sodium Bicarbonate Baking soda po 2d Sodium citrate Nutradex po No race day medication. Stanozolol Stanazol i/m 22d (25d on multiples) St John Wart Various po 3d Terbinafine HCl Lamisil Topical Nil Terbutaline Bricanyl inhalation 3d Testosterone Depot Depandrol i/m 10ml 18d Testosterone Enanthate Anadocalin i/m 125mg 22d NZEVA Page 4 of 5 NZEVA Prohibited Substance Recommended Withholding Times October 2011 Name of Drug Brand Name Route Dose Recommended Withholding Times (days) Testosterone Propionate AVP Supertest i/m 250mg 11+d Testosterone Suspension RWR Testosterone Susp. i/m 500mg 22d Tetracycline HCl Engemycin etc i/v Nil Theobromine 7d Theophylline Bykophyllin pellets po 6g 8d Thyroxin Various po Nil Transexamic Acid Vasolamin 3d Triamcinolone Kenacort 10 i/a 20mg 4d Trichloromethiazine Naquasone po 4d Trimethoprim Tribrissen inj, Sulpha-T paste, etc po,i/v Nil Tripelennamine i/m 8d Valerian Various po 3d Vaccines against infectious agents Nil Vedaprofen Quadrisol po,i/v 1gm 8d Virginiamycin Founderguard po Nil White willow plant - salicylate po 3d Xylazine AnasedTM 100mg/ml solution i/v 2.2mg/kg 4d Xylometazolidine Otrivin intra nasal 4d NZEVA Page 5 of 5.
Recommended publications
  • Anabolic-Androgenic Steroids in Horses: Natural Presence and Underlying Biomechanisms
    ANABOLIC-ANDROGENIC STEROIDS IN HORSES: NATURAL PRESENCE AND UNDERLYING BIOMECHANISMS Anneleen Decloedt Dissertation submitted in the fulfilment of the requirements for the degree of Doctor of philosophy (PhD) in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University PROMOTER Prof. dr. ir. Lynn Vanhaecke Ghent University, Faculty of Veterinary Medicine Department of Veterinary Public Health and Food Safety Laboratory of Chemical Analysis MEMBERS OF THE READING COMMITTEE Prof. dr. James Scarth HFL Sport Science, Cambridgeshire, United-Kingdom Prof. dr. Peter Van Eenoo Ghent University, DoCoLab, Zwijnaarde, Belgium Prof. dr. Ann Van Soom Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium MEMBERS OF THE EXAMINATION COMMITTEE Dr. Ludovic Bailly-Chouriberry Laboratoires des Courses Hippiques, Verrières-le-Buisson, France Dr. Leen Van Ginkel Wageningen University, RIKILT, Wageningen, The Netherlands Prof. dr. Myriam Hesta Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium This work was funded by the Fédération Nationale des Courses Françaises (via the Laboratoire des Courses Hippiques) and executed at the Laboratory of Chemical Analysis (Faculty of Veterinary Medicine, Ghent University, Merelbeke). The author and the promoter give the authorisation to consult and to copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author. “The universe is full of magic, Just patiently waiting for our wits to grow sharper” TABLE OF CONTENTS TABLE OF CONTENTS Chapter I – General Introduction 1 1. Steroids 3 1.1 Chemical structure 1.2 (Steroid) hormones and their role in the endocrine system 1.3 Biosynthesis of steroid hormones 1.4 Anabolic-androgenic steroids (AAS) 1.5 Synthesis and absorption of the steroid precursor cholesterol 2.
    [Show full text]
  • Health Reports for Mutual Recognition of Medical Prescriptions: State of Play
    The information and views set out in this report are those of the author(s) and do not necessarily reflect the official opinion of the European Union. Neither the European Union institutions and bodies nor any person acting on their behalf may be held responsible for the use which may be made of the information contained therein. Executive Agency for Health and Consumers Health Reports for Mutual Recognition of Medical Prescriptions: State of Play 24 January 2012 Final Report Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Acknowledgements Matrix Insight Ltd would like to thank everyone who has contributed to this research. We are especially grateful to the following institutions for their support throughout the study: the Pharmaceutical Group of the European Union (PGEU) including their national member associations in Denmark, France, Germany, Greece, the Netherlands, Poland and the United Kingdom; the European Medical Association (EMANET); the Observatoire Social Européen (OSE); and The Netherlands Institute for Health Service Research (NIVEL). For questions about the report, please contact Dr Gabriele Birnberg ([email protected] ). Matrix Insight | 24 January 2012 2 Health Reports for Mutual Recognition of Medical Prescriptions: State of Play Executive Summary This study has been carried out in the context of Directive 2011/24/EU of the European Parliament and of the Council of 9 March 2011 on the application of patients’ rights in cross- border healthcare (CBHC). The CBHC Directive stipulates that the European Commission shall adopt measures to facilitate the recognition of prescriptions issued in another Member State (Article 11). At the time of submission of this report, the European Commission was preparing an impact assessment with regards to these measures, designed to help implement Article 11.
    [Show full text]
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub
    US 20090005722A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2009/0005722 A1 Jennings-Spring (43) Pub. Date: Jan. 1, 2009 (54) SKIN-CONTACTING-ADHESIVE FREE Publication Classification DRESSING (51) Int. Cl. Inventor: Barbara Jennings-Spring, Jupiter, A61N L/30 (2006.01) (76) A6F I3/00 (2006.01) FL (US) A6IL I5/00 (2006.01) Correspondence Address: AOIG 7/06 (2006.01) Irving M. Fishman AOIG 7/04 (2006.01) c/o Cohen, Tauber, Spievack and Wagner (52) U.S. Cl. .................. 604/20: 602/43: 602/48; 4771.5; Suite 2400, 420 Lexington Avenue 47/13 New York, NY 10170 (US) (57) ABSTRACT (21) Appl. No.: 12/231,104 A dressing having a flexible sleeve shaped to accommodate a Substantially cylindrical body portion, the sleeve having a (22) Filed: Aug. 29, 2008 lining which is substantially non-adherent to the body part being bandaged and having a peripheral securement means Related U.S. Application Data which attaches two peripheral portions to each other without (63) Continuation-in-part of application No. 1 1/434,689, those portions being circumferentially adhered to the sleeve filed on May 16, 2006. portion. Patent Application Publication Jan. 1, 2009 Sheet 1 of 9 US 2009/0005722 A1 Patent Application Publication Jan. 1, 2009 Sheet 2 of 9 US 2009/0005722 A1 10 8 F.G. 5 Patent Application Publication Jan. 1, 2009 Sheet 3 of 9 US 2009/0005722 A1 13 FIG.6 2 - Y TIII Till "T fift 11 10 FIG.7 8 13 6 - 12 - Timir" "in "in "MINIII.
    [Show full text]
  • A28 Anabolic Steroids
    Anabolic SteroidsSteroids A guide for users & professionals his booklet is designed to provide information about the use of anabolic steroids and some of the other drugs Tthat are used in conjunction with them. We have tried to keep the booklet free from technical jargon but on occasions it has proven necessary to include some medical, chemical or biological terminology. I hope that this will not prevent the information being accessible to all readers. The first section explaining how steroids work is the most complex, but it gets easier to understand after that (promise). The booklet is not intended to encourage anyone to use these drugs but provides basic information about how they work, how they are used and the possible consequences of using them. Anabolic Steroids A guide for users & professionals Contents Introduction .........................................................7 Formation of Testosterone ...............................................................8 Method of Action ..............................................................................9 How Steroids Work (illustration).......................................................10 Section 1 How Steroids are Used ....................................... 13 What Steroid? ................................................................................ 14 How Much to Use? ......................................................................... 15 Length of Courses? ........................................................................ 15 How Often to Use Steroids?
    [Show full text]
  • DHEA Sulfate, and Aging: Contribution of the Dheage Study to a Sociobiomedical Issue
    Dehydroepiandrosterone (DHEA), DHEA sulfate, and aging: Contribution of the DHEAge Study to a sociobiomedical issue Etienne-Emile Baulieua,b, Guy Thomasc, Sylvie Legraind, Najiba Lahloue, Marc Rogere, Brigitte Debuiref, Veronique Faucounaug, Laurence Girardh, Marie-Pierre Hervyi, Florence Latourj, Marie-Ce´ line Leaudk, Amina Mokranel, He´ le` ne Pitti-Ferrandim, Christophe Trivallef, Olivier de Lacharrie` ren, Stephanie Nouveaun, Brigitte Rakoto-Arisono, Jean-Claude Souberbiellep, Jocelyne Raisonq, Yves Le Boucr, Agathe Raynaudr, Xavier Girerdq, and Franc¸oise Foretteg,j aInstitut National de la Sante´et de la Recherche Me´dicale Unit 488 and Colle`ge de France, 94276 Le Kremlin-Biceˆtre, France; cInstitut National de la Sante´et de la Recherche Me´dicale Unit 444, Hoˆpital Saint-Antoine, 75012 Paris, France; dHoˆpital Bichat, 75877 Paris, France; eHoˆpital Saint-Vincent de Paul, 75014 Paris, France; fHoˆpital Paul Brousse, 94804 Villejuif, France; gFondation Nationale de Ge´rontologie, 75016 Paris, France; hHoˆpital Charles Foix, 94205 Ivry, France; iHoˆpital de Biceˆtre, 94275 Biceˆtre, France; jHoˆpital Broca, 75013 Paris, France; kCentre Jack-Senet, 75015 Paris, France; lHoˆpital Sainte-Perine, 75016 Paris, France; mObservatoire de l’Age, 75017 Paris, France; nL’Ore´al, 92583 Clichy, France; oInstitut de Sexologie, 75116 Paris, France; pHoˆpital Necker, 75015 Paris, France; qHoˆpital Broussais, 75014 Paris, France; and rHoˆpital Trousseau, 75012 Paris, France Contributed by Etienne-Emile Baulieu, December 23, 1999 The secretion and the blood levels of the adrenal steroid dehydro- number of consumers. Extravagant publicity based on fantasy epiandrosterone (DHEA) and its sulfate ester (DHEAS) decrease pro- (‘‘fountain of youth,’’ ‘‘miracle pill’’) or pseudoscientific asser- foundly with age, and the question is posed whether administration tion (‘‘mother hormone,’’ ‘‘antidote for aging’’) has led to of the steroid to compensate for the decline counteracts defects unfounded radical assertions, from superactivity (‘‘keep young,’’ associated with aging.
    [Show full text]
  • Miscellaneous Projects 2004
    In: W Schänzer, H Geyer, A Gotzmann, U Mareck (eds.) Recent Advances In Doping Analysis (13). Sport und Buch Strauß - Köln 2005 R. Kazlauskas Miscellaneous Projects 2004 Australian Sports Drug Testing Laboratory, National Measurement Institute, 1 Suakin St., Pymble, NSW 2073 Australia. Background This paper covers a collection of small projects which may be considered as topical for our laboratory over the past year or so. These are a continuation of the study of elimination studies using available substituted nandrolone analogues, the issue of obtaining reasonable results for morphine and especially codeine analysis taking into account the poor hydrolysis of codeine glucuronide and some important observations on the analysis of hCG in the presence of urines which contain sediment. Designer drugs based on substituted nandrolones In the Cologne Workshop in 2004 a talk was presented on some methyl-susbtituted nandrolone analogues, namely 18-methylnandrolone and 7a-methylnandrolone (MENT) (Kazlauskas, 2004). Other substituted nandrolone derivatives that were available commercially were 17α-methylnandrolone, 4-fluoronandrolone and 19-norclostebol. All studies were carried out by our routine steroid screening procedure. To the urine (3 mL) were added internal standards, 0.2 M phosphate buffer pH 7, E. coli glucuronidase and the mix was incubated at 50 oC for 1.5 h. The mixture was loaded onto a 3M Empore C18 cartridge (using the automated Gilson ASPEC system) and eluted with water, 25% methanol/water, hexane and the steroids eluted with 5% ethyl acetate/methanol. The collected fraction was evaporated to dryness and derivatised with MSTFA/TMSI/ethanethiol. The sample (3 uL) was injected onto an Agilent 6890/5973 mass spectrometer using an Agilent HP1 column, 17 m length, 0.20 mm id, and 0.11 um film thickness.
    [Show full text]
  • H|||||||||I|| USOOSO91 189A United States Patent (19) 11 Patent Number: 5,091,189 Heafield Et Al
    H|||||||||I|| USOOSO91 189A United States Patent (19) 11 Patent Number: 5,091,189 Heafield et al. l 45) Date of Patent: Feb. 25, 1992 54 CONTROLLED RELEASE DOSAGE FORMS (56) References Cited HAVING A DEFINED WATER CONTENT U.S. PATENT DOCUMENTS 3,965,256 6/1976 Leslie.................................... 424/22 75 Inventors: Joanne Heafield; Stewart I. Leslie; 4,743,247 5/1988 Wong .................................. 424/468 Sandra T. A. Malkowska; Philip J. Neale, all of Cambridge, United 4,753,800 6/1988 Mozda ................................. 424/440 Kingdom 4,844,910 7/1989 Leslie et al. ......................... 424/470 FOREIGN PATENT DOCUMENTS 73) Assignee: Euroceltique S.A., Luxembourg, 97523 1/1984 European Pat. Off. Luxembourg 109320 6/1986 European Pat. Off. 251459 1/1988 European Pat. Off. 21 Appl. No.: 704,714 270305 6/1988 European Pat. Off. Primary Examiner-Thurman K. Page (22 Filed: May 17, 1991 Assistant Examiner-Leon R. Horne Attorney, Agent, or Firm-Nixon & Vanderhye Related U.S. Application Data (57) ABSTRACT A controlled release, solid, oral dosage form containing 63 Continuation of Ser. No. 355,417, May 23, 1989, aban a 3-alkylxanthine, preferably theophylline, at least one doned. hydrophilic or hydrophobic polymer, at least one wax having a melting point between 25' and 90° C. and (30) Foreign Application Priority Data between 3% and 10% (by weight) water. Jun. 2, 1988 GB) United Kingdom ................. 88.3064 Preferably the dosage form is a tablet and the water content is between 4% and 9% (by weight). The 51) Int. Cl................................................. A61K 9/52 amount of water present in the dosage form determines 52 U.S.
    [Show full text]
  • BP601T Medicinal Chemistry III (Theory) UNIT II Prepared By- Mrs. Sneha Kushwaha Assistant Professor Rama University Kanpur Anti
    BP601T Medicinal Chemistry III (Theory) UNIT II Prepared by- Mrs. Sneha Kushwaha Assistant Professor Rama University Kanpur Unit II 10 Hours Antibiotics Historical background, Nomenclature, Stereochemistry, Structure activity relationship Chemical degradation classification and important products of the following classes Macrolide: Erythromycin, Clarithromycin, Azithromycin. Miscellaneous: Chloramphenicol*, Clindamycin. Prodrugs: Basic concepts and application of prodrug design. Antimalarials: Etiology of malaria. Quinolines: SAR, Quinine sulphate, Chloroquine*, Amodiaquine, Primaquine phosphate, Pamaquine*, Quinacrine hydrochloride, Mefloquine. Biguanides and dihydro triazines: Cycloguanil pamoate, Proguanil. Miscellaneous: Pyrimethamine, Artesunete, Artemether, Atovoquone. Antibiotics B.Pharma – 3rd Year VI Sem. UNIT II – Antibiotics By - Sneha Kushwaha (Asst. Professor) Subject – Medicinal Chemistry (BP601 T) Macrolide Antibiotics Introduction The macrolides are a class of natural products that consist of a large macrocyclic lactone ring to which one or more deoxy sugars, usually cladinose and desosamine, may be attached. The lactone rings are usually 14-, 15-, or 16-membered. Macrolides belong to the polyketide class of natural products History The first macrolide discovered was erythromycin, which was first used in 1952. Erythromycin was widely used as a substitute to penicillin in cases where patients were allergic to penicillin or had penicillin-resistant illnesses. Later macrolides developed, including azithromycin and clarithromycin,
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev
    Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2008) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM GADOCOLETICUM 280776-87-6 ABAFUNGIN 129639-79-8 ACIDUM LIDADRONICUM 63132-38-7 ABAMECTIN 65195-55-3 ACIDUM SALCAPROZICUM 183990-46-7 ABANOQUIL 90402-40-7 ACIDUM SALCLOBUZICUM 387825-03-8 ABAPERIDONUM 183849-43-6 ACIFRAN 72420-38-3 ABARELIX 183552-38-7 ACIPIMOX 51037-30-0 ABATACEPTUM 332348-12-6 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABETIMUSUM 167362-48-3 ACIVICIN 42228-92-2 ABIRATERONE 154229-19-3 ACLANTATE 39633-62-0 ABITESARTAN 137882-98-5 ACLARUBICIN 57576-44-0 ABLUKAST 96566-25-5 ACLATONIUM NAPADISILATE 55077-30-0 ABRINEURINUM 178535-93-8 ACODAZOLE 79152-85-5 ABUNIDAZOLE 91017-58-2 ACOLBIFENUM 182167-02-8 ACADESINE 2627-69-2 ACONIAZIDE 13410-86-1 ACAMPROSATE
    [Show full text]